Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 15/20 | 0.48 |
| ▸ | NMBR | P28336 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5689085 | 0.87 | SIRT2 (0.48) | SIRT2NMBRCYP11B1CYP11B2CPB1 | |
| SCHEMBL12662604 | 0.84 | SIRT2 (0.45) | SIRT2NMBRCYP11B1CYP11B2CPB1 | |
| SCHEMBL2033093 | 0.84 | SIRT2 (0.45) | SIRT2NMBRCYP11B1CYP11B2CPB1 | |
| SCHEMBL27015285 | 0.83 | SIRT2 (0.52) | SIRT2NMBRCPB1CPB2 | |
| SCHEMBL1997674 | 0.83 | SIRT2 (0.52) | SIRT2NMBRCPB1CPB2 | |
| SCHEMBL1342 | 0.82 | SIRT2 (0.45) | SIRT2NMBRCYP11B1CYP11B2 | |
| SCHEMBL23278626 | 0.81 | SIRT2 (0.43) | SIRT2NMBRCYP11B1CYP11B2CPB1 | |
| SCHEMBL4904608 | 0.81 | SIRT2 (0.45) | SIRT2NMBRCYP11B1CYP11B2 | |
| SCHEMBL222977 | 0.81 | SIRT2 (0.44) | SIRT2NMBRCYP11B1CYP11B2 | |
| SCHEMBL6771514 | 0.80 | SIRT2 (0.44) | SIRT2NMBRCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222174-A1 | IMIDAZOL-4-YLMETHANOLS USED AS INHIBITORS OF STEROID C17-20 LYASE | Takeda Chemical Industries, Ltd. (JP) | 2002-07-17 | — | — | EP | disclosed |
| US-20010047100-A1 | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives | KJAERSGAARD HANS JOERGEN (DK) | 2001-11-29 | — | — | US | disclosed |
| WO-2001081317-A1 | CHIRAL IMIDAZOYL INTERMEDIATES FOR THE SYNTHESIS OF 2-(4-IMIDAZOYL)-CYCLOPROPYL DERIVATIVES | GLIATECH, INC. (US) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001030762-A1 | IMIDAZOL-4-YLMETHANOLS USE AS INHIBITORS OF STEROID C17-20 LYASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047100-A1 | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives | HRH4, HRH2, HRH1 | SIRT2 2591/4885NMBR 582/4885CYP11B1 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.